Mitochondrial DNA deletions in oculopharyngeal muscular dystrophy  by Lezza, Angela M.S et al.
FEBS 19522 FEBS Letters 418 (1997) 167-170 
Mitochondrial DNA deletions in oculopharyngeal muscular dystrophy 
Angela M.S. Lezzaa, Antonella Cormioa, Patrizia Gerardia, Gabriella Silvestrib, 
Serena Servideib, Luigi Serlengac, Palmiro Cantatorea, Maria Nicola Gadaletaa'* 
"Department of Biochemistry and Molecular Biology and CNR Unit for the Study of Mitochondria and Energetic Metabolism, 
University of Bari, Via Orabona, 4, 70125 Bari, Italy 
bInstitute of Neurology, Catholic University, L.go Vito 1, 00168 Rome, Italy 
cInstitute of Neurology, University of Bari, P.zza G. Cesare, 70124 Bari, Italy 
Received 14 October 1997 
Abstract The deletions in the mitochondrial DNA from skeletal 
muscle samples of two oculopharyngeal muscular dystrophy 
cases were studied using polymerase chain reaction techniques. 
The 4977 bp 'common deletion' was present in both specimens, 
exceeding the corresponding values of similarly aged, healthy 
controls. In the two samples multiple different mitochondrial 
DNA deletions, some case-specific and present at quite high, 
although not pathogenetic levels, were observed. The results 
suggest that mitochondrial DNA deletions, and the 'common 
deletion' in particular, might be a sensitive and early marker 
of a generalized mitochondrial suffering, due to a variety of 
pathological and physiological causes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Oculopharyngeal muscular dystrophy (OPMD) is a late-on-
set muscle disease associated with progressive ptosis of the 
eyelids and dysphagia which is inherited as an autosomal 
dominant trait with complete penetrance and without sex 
preference [1]. A disease locus has recently been mapped 
through linkage analysis to a region of less than 5 cM on 
chromosome 14qll.2-ql3 [2]. The markers closest to the locus 
are two cardiac a and P heavy chain myosin genes which raise 
some intriguing possibilities about the pathogenetic mecha-
nism. The disease usually manifests itself in the fifth or sixth 
decade at the level of the levator palpebrae and pharyngeal 
muscles, later all extraocular and other voluntary muscles may 
become affected resulting, finally, in undernutrition and, even-
tually, in death by starvation or by aspiration pneumonia 
because there is no known therapy by drugs or other means 
[!]■ 
The frequency of OPMD in France has been estimated to 
be at least 1 in 200 000 and probably from France (in the first 
half of the 17th century) people carrying a single OPMD 
mutation (which has been traced back that far) emigrated to 
Quebec spreading the disease there [1]. In fact, numerous 
familial cases of OPMD have been reported in the French 
Canadian community. 
There are several histological changes in the OPMD-af-
fected muscles, but most of them are common to many mus-
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cular dystrophies, whereas the real hallmark of the disease is 
the presence of tubulofilamentous intranuclear inclusions of 
yet unknown origin [1]. The histological marker, in particular, 
is very helpful in differentiating OPMD from other myopa-
thies such as the mitochondrial myopathies, especially the 
oculocraniosomatic disease with ragged red fibers (RRF) or 
Kearns-Sayre syndrome (KSS) [3] and the autosomal domi-
nant mitochondrial myopathy with PEO and bilateral cataract 
(ad-PEO) [4], which share with OPMD the involvement of the 
ocular muscle, or te myasthenia gravis. RRF and mitochon-
drial morphological alterations are not a feature of OPMD 
although the presence of bizarre cristae inside enlarged organ-
elles and/or of electron-dense homogeneous material inside 
the matrix have been reported by some authors [5,6]. These 
authors, together with other researchers [7], have raised the 
possibility of a central role of mitochondrial dysfunction in 
OPMD. The issue has been a controversial one especially 
because RRF and other mitochondrial morphological altera-
tions as well as defects of the respiratory chain enzymes have 
been reported occasionally in aging subjects [1,8] and always 
in KSS patients [1]. However, the quite definitive mapping of 
the OPMD locus to a nuclear gene has completely ruled out 
the etiopathological relevance of mitochondria for the disease. 
Recently, the analysis of mitochondrial DNA (mtDNA) in 
ocular myopathies has become a diagnostic criterion. In par-
ticular, Rowland and coworkers [9] have studied the mtDNA 
of an OPMD patient belonging to one of the largest French-
Canadian affected pedigrees by means of Southern hybridiza-
tion without finding deletions of the organelle genome. In 
contrast, the proportion of deleted molecules detected by 
Southern hybridization ranged from 45% to 85% [4,10] in 
patients affected by KSS or ad-PEO. 
It had also been suggested that OPMD might be a genet-
ically determined 'senescent myopathy' [11] and since we have 
previously reported an age-related accumulation of mtDNA 
deletions in the skeletal muscle of healthy aging human sub-
jects [12], we have analyzed the mtDNA of two unrelated 
cases of OPMD in order to compare these data with those 
of similarly aged, healthy subjects. 
2. Materials and methods 
2.1. Human subjects and tissues 
Patient 1 (O.R.) was a 61 year old man with a clinically denned 
form of familial dominant OPMD. A skeletal muscle biopsy was 
obtained from his left biceps muscle and it showed myopathy aspecific 
signs. Staining for cytochrome c oxidase (Cox) and succinate dehy-
drogenase (SDH) activities showed rare RRFs-Cox-negative fibers in 
the sections. The morphological examination did not demonstrate the 
frequent, but not disease-specific, rimmed vacuoles. The biochemical 
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assays carried out (according to [13]) on the muscle homogenate were 
all in the normal range. 
Patient 2 (G.F.) was a 63 year old man with a clinically diagnosed 
autosomal dominant form of OPMD. A skeletal muscle biopsy was 
obtained from his left deltoid muscle and it showed a tendency to type 
I fiber hypotrophy. Staining for Cox and SDH activities did not show 
any RRF or any Cox-negative fibers. 
2.2. DNA isolation, polymerase chain reaction (PCR) and DNA 
sequencing 
Total mtDNA was extracted according to described procedures 
[12]. The analysis of the patient and control mtDNAs was performed 
by means of PCR. Fragments of mtDNA from both patients and 
healthy controls were amplified using conditions previously estab-
lished [12]. Nucleotide positions of primers refer to the L-strand se-
quence of mtDNA with the 5'-end preceding the 3'-end. The primer 
pair ND1 For (3007-3023) - 3.5 Rev (3538-3520) amplified a 531 bp 
fragment from total mtDNA; the primer pair ATP For (8282-8305) -
13 Rev bis (13928-13905) amplified only the 669 bp fragment from 
4977 bp deleted mtDNA (mtDNA4977) since the 5646 bp fragment 
from wild-type mtDNA was too long to be produced with a short 
elongation time. The primer pairs 8.1 For (8150-8166) - 16.1 Rev 
(16159-16141), ATP For - 16.1 Rev and 8.3 For (8361-8380) - 16.1 
Rev coamplified products of various lengths from different coexisting 
deleted species of mtDNA. The double-stranded PCR products from 
deleted mtDNAs were separated by electrophoresis on 1% Sea-Plaque 
(FMC) agarose gels in lXTAE (40 mM Tris-acetate pH 7.8, 1 mM 
EDTA) buffer and detected by ethidium bromide staining under UV 
light. The bands were excised and treated with the Qiaex gel extrac-
tion kit (Qiagen). Sequencing reactions were performed with these 
templates according to [14] using 0.5 pmol 5' [y-32P]ATP-labeled pri-
mer in 10 |xl reaction mixtures containing: 30 mM Tris-HCl pH 9.0, 
4 mM MgCl2, 10 uM of each dNTP, double-stranded PCR-amplified 
DNA in water, 0.1 mM ddGTP or 0.3 mM ddATP or 0.4 mM ddTTP 
or 0.2 mM ddCTP and 0.5 units Taq DNA polymerase (Boehringer 
Mannheim). The reactions were overlaid with 10 ul of mineral oil, 
incubated in a thermal cycler for 20 cycles (30 s at 94°C, 30 s at 55°C 
and 60 s at 72°C), followed by 10 cycles (30 s at 94°C and 60 s at 
72°C) and terminated by the addition of 5 ul formamide dye solution. 
The quantitative dosages were performed as described in [12] for 
total mtDNA and the various species of deleted mtDNA. 
3. Results 
The mtDNA from the skeletal muscle of patient 1 with 
OPMD had not revealed large rearrangements when tested 
by means of Southern blot hybridization (data not shown) 
and we analyzed it with PCR. We looked for the 4977 bp 
deletion, also known as the 'common deletion' because of 
its frequency in cases of mitochondrial pathology, in the 
mtDNAs of patient 1 as well as of a similarly aged, healthy 
control (58 years old). The amplification with the primer pair 
ATP For-13 Rev bis of the same amount of mtDNA from 
both samples suggested a quite large presence of the deleted 
species in the patient mtDNA by comparing the intensities of 
the ethidium bromide-stained PCR products (Fig. 1). 
Testing the OPMD patient mtDNA for the presence of 
Table 1 
Nucleotide sequences of the deletion breakpoints in OPMD patient 1 
Deletion size (bp) Sequence 
4977 8470 
ACCTCCCTCACCA(AAG 
7679 8387 
ACTACCG(TAT 
7436 8629 
ACCTCCA(AAT 
7240 8697 
ACAAATG(ATA 
Fig. 1. PCR analysis of mtDNA from OPMD patient 1 (lane 1) 
and a similarly aged (58 years) healthy control (lane 2). The amplifi-
cation was carried out using the same amount of mtDNA template. 
The PCR product of 669 bp derives from the 4977 bp deleted 
mtDNA molecules. Lane M contains molecular size markers (bp). 
other deletions by means of a different primer pair (8.1 For-
16.1 Rev) three different products coamplified. The identities 
of these products were assessed through primer shift PCR and 
sequencing reactions [15]. We identified three deletions, of 
7240 bp, 7436 bp and 7679 bp (Table 1). The 7436 bp deletion 
(nt 8630-16065) in this OPMD patient did not exactly coin-
cide with the same size deletion described in various tissues 
[16-18] of aging subjects. Patient l's mtDNA7436 was not de-
limited by any direct repeat, although its 3' end was still 
located very close to that 'hot-spot' region (16068-16079) 
where the 3' ends of many other described mtDNA deletions 
map [4,19]. Also the 7240 bp and the 7679 bp deletions were 
not reported before, they were not enclosed by direct repeats 
and were located, respectively, mtDNA7679 between positions 
8388 and 16066 and mtDNA7240 between positions 8698 and 
15 937. 
We then measured the levels of the mtDNA4977 and of the 
other deleted species in this OPMD patient with the method 
described in [12]. The results are reported in Table 2. The 
'common deletion' is the most represented one with a 4.5% 
level, which is 64-fold higher than the value in the similarly 
aged control (0.07%). It is followed by the 7679 bp deletion 
(3.2%o), whereas the other two deletions show lower levels 
(0.002% for the mtDNA7436 and 0.1% for the mtDNA7240). 
The mtDNA of OPMD patient 2 was analyzed by means of 
PCR for the presence of deletions. Three deleted species were 
identified, encompassing, respectively, 4977 bp, 7436 bp and 
7138 bp (Fig. 2). The 4977 bp deletion was the 'common' one 
already described. The 7436 bp deletion of this OPMD patient 
showed the same breakpoints reported by other authors in 
aging healthy subjects, spanning from position 8637 through 
Direct repeat 
13447 13 bp 
AACCTCCCTCACCA)TTG 
16067 None 
ATTGA)CTC 
16066 None 
TATTG)ACT 
15938 None 
GAAAA)CCT 
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Table 2 
MtDNA deletion levels in OPMD patients 
Sample OPMD patient 1 (61 years) OPMD patient 2 (63 years) Control" (58 years) Control" (65 years) 
% mtDNA4977 4.5 2.7 0.07 0.06 
fold increase compared to controls 64 45 1 1 
% mtDNA7436 0.002 0.00007 N.D. 
% mtDNA7240 0.1 - - -
% mtDNA7679 3.2 
% mtDNA7138 - 0.06 
— = not present; N.D. = not detemined. 
"Values are from [12]. 
position 16072 and being enclosed by two 12 nt direct repeats 
at nt 8637-8648 and 16073-16084. The 7138 bp deletion 
spanned from nt positions 8605 through 15 741 and was not 
delimited by direct repeats. 
We quantified the deletions with the same PCR kinetic 
method [12], obtaining the results shown in Table 2. Also in 
this case the mtDNA4977 shows the highest percentage of 
2.7%, which is 45-fold higher than the value of the similarly 
aged (65 years old) control (0.06%). In contrast, the other two 
deletions are quite poorly represented reaching 0.06%> for the 
mtDNA7138 and 0.00007% for the mtDNA7436. 
We demonstrated the presence in the skeletal muscle of 
various, similarly aged, healthy controls of different mtDNA 
deletions besides the 'common deletion'. However, their levels 
were too low to be quantified in a reliable way while being 
synchronously coamplified by a single primer pair (results not 
shown). 
4. Discussion 
In conclusion, both our OPMD patients did not present 
Southern-detectable levels of deleted mtDNA in their skeletal 
muscle. In fact, only the PCR technique could find various 
species of deleted mtDNA in the two analyzed OPMD cases. 
The 'common deletion' was present in both patients whereas 
other deletions were case-specific (see Table 2) and were usu-
ally not enclosed by direct repeats. This last condition has 
Fig. 2. PCR analysis of mtDNA from OPMD patient 2. The ampli-
fication was performed with the primer pair 8.3 For-16.1 Rev and 
two faint bands, of 661 bp and 363 bp, are visible in lane 1. The 
661 bp product was excised, cycle-sequenced and demonstrated to 
derive from a 7138 bp long deletion. The 363 bp product, treated 
with the same procedure, was demonstrated to derive from the al-
ready described deletion of 7436 bp. Lane M contains molecular 
size markers (bp). 
been already described in aging healthy subjects [20] as well 
as patients [21,22] suffering from various kinds of pathology. 
We have quantified the level of the 4977 bp deletion and of 
the other deletions by means of our quantitative method dem-
onstrating a quite important increase (45-64-fold) of the 
'common deletion' with respect to the values of the similarly 
aged controls (Table 2). An explanation for this suggests that 
the 'common deletion' might be a marker of generalized mi-
tochondrial suffering in the skeletal muscles affected by the 
disease. In fact, some recent papers have shown that various 
pathologies, sporadic or inherited in a mendelian way and 
affecting the skeletal muscle, are associated with an increased 
level of mtDNA large deletions including the 'common dele-
tion'. Among such pathologies are: sporadic inclusion body 
myositis [23], chronic hypoxia [24], polymyalgia rheumatica 
[25] and myotonic dystrophy [26,27], where the high sensitiv-
ity of the PCR has allowed the detection of deleted mtDNA 
molecules with a higher frequency than in the control counter-
parts. In most of the cited studies, however, no quantitative 
dosage of the deleted mtDNA has ever been performed. 
In contrasty, in other pathologies where there is a direct 
involvement of the mitochondrial genome through a probable 
nuclear gene controlling its integrity as in Wolfram syndrome 
[28], ad-PEO and cataract [4] and familial mitochondrial myo-
pathy [29,30], the mtDNA deletion level increases reaching 
high percentages (56-80%), detectable by Southern blot and 
affecting the bioenergetic capacity of the organelle. This is 
suggested by the deficit of various respiratory chain complexes 
[28] or the decrease of a specific subunit of the ATP synthase 
complex [30], demonstrated in some pathologies inherited as 
mendelian traits. A defect of the bioenergetic capacity, in 
contrast, is generally not present in the OPMD cases, which 
do not show defects of the respiratory complexes, supporting 
our idea of the mtDNA deletions as a sensitive and early 
marker of a generalized mitochondrial suffering [31,32]. 
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